| 证券代码：603976 | 证券简称：正川股份 | 公告编号：2025-050 | | --- | --- | --- | | 债券代码：113624 | 债券简称：正川转债 | | 重庆正川医药包装材料股份有限公司 第四届监事会第十六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 息披露媒体上披露的《2025 年半年度报告》及《2025 年半年度报告摘要》。 2、审议通过了《2025 年半年度募集资金存放与实际使用情况的专项报告》 报告期内，公司按《上市公司募集资金监管规则》《上海证券交易所上市公 司自律监管指引第 1 号——规范运作（2025 年 5 月修订）》和公司募集资金使用 管理办法的相关规定及时、真实、准确、完整披露募集资金的存放与使用情况， 不存在违规使用募集资金的情形。 重庆正川医药包装材料股份有限公司（以下简称"公司"）于 2025 年 8 月 12 日以电子邮件或电话等形式向各位监事发出了召开第四届监事会第十六次会 议的通知。会议于 2025 年 8 月 22 日 ...

| | | 重庆正川医药包装材料股份有限公司 第四届董事会第二十三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 重庆正川医药包装材料股份有限公司（以下简称"公司"）于 2025 年 8 月 12 日以电子邮件或电话等形式向各位董事发出了召开第四届董事会第二十三次 会议的通知。会议于 2025 年 8 月 22 日以现场结合通讯方式在正川永成公司三楼 会议室召开，应参加董事 9 名，实际参加董事 9 名。 本次会议由董事长邓勇先生召集和主持，公司全体监事及相关人员列席了会 议。本次会议的召集、召开和表决程序均符合《公司法》等法律、行政法规以及 《公司章程》《公司董事会议事规则》的有关规定，会议的召集、召开合法有效。 二、董事会会议审议情况 1、审议通过了《2025 年半年度报告及其摘要》 公司 2025 年半年度报告及其摘要的编制程序符合法律、法规、《公司章程》 和公司管理制度的各项规定；本次半年度报告的内容真实、准确、完整，不存在 任何虚假记载、误导性陈述或者重大遗漏，报告客观地反映了 ...

重庆正川医药包装材料股份有限公司2025 年半年度报告 公司代码：603976 公司简称：正川股份 重庆正川医药包装材料股份有限公司 2025 年半年度报告 1 / 148 重庆正川医药包装材料股份有限公司2025 年半年度报告 重要提示 本报告所涉及的未来计划、发展战略等前瞻性陈述，不构成公司对投资者的实质承诺，请投 资者注意投资风险。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人邓勇、主管会计工作负责人邓勇及会计机构负责人（会计主管人员）肖汉容声 明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 八、 是否存在违反规定决策程序对外提供担保的情况 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 ...

Core Insights - The Chinese borosilicate glass industry is primarily focused on the midstream manufacturing segment, with key applications in medical institutions and pharmaceutical logistics [1][2]. Industry Overview - The upstream raw materials for the borosilicate glass industry include quartz sand, borax, cullet, calcite, and feldspar, with major production equipment being muffle furnaces and draw machines [1]. - Key upstream suppliers include quartz sand leader Quartz Corporation and international institutions like Corning for glass raw materials [2]. Regional Distribution - The borosilicate glass industry is concentrated in the eastern coastal regions of China, particularly in Jiangsu Province, indicating a regional heat map of production [6]. Company Performance - In 2024, Shandong Pharmaceutical Glass and Zhengchuan Co. have nearly 100% sales rates, while Linuo Pharmaceutical's sales rate is below 90% [8]. - Shandong Pharmaceutical Glass has a high overall business gross margin, while Linuo Pharmaceutical and Zhengchuan Co. have gross margins around 22%-23% [8]. Company Developments - Shandong Pharmaceutical Glass plans to achieve an annual production capacity of 2.4-2.5 billion borosilicate molded bottles by mid-2025, with an expected total capacity exceeding 5 billion by the end of 2025 [10]. - Linuo Pharmaceutical announced the acquisition of a 51% stake in an Egyptian pharmaceutical glass manufacturer, aiming to establish a production base in North Africa [10]. - Qibin Group is set to start trial production of two 50 tons/day borosilicate pharmaceutical glass tube production lines in Luzhou, Sichuan, by October 2024 [10]. - Weigao Co. aims to increase its pre-filled syringe production capacity from 800 million units in 2023 to 1.2 billion units by 2025, targeting a global market share of 35% [10]. - Zhengchuan Co. plans to launch a 300 million unit pre-filled syringe production line in early 2025, with a second phase project to start by the end of 2025 [10].

Core Viewpoint - Zhengchuan Co., Ltd. has a closing price of 21.79 yuan, with a rolling PE ratio of 76.42 times, indicating a higher valuation compared to the industry average [1] Company Summary - Zhengchuan Co., Ltd. specializes in the research, production, and sales of pharmaceutical packaging materials, including borosilicate glass tubes and pre-filled syringes [1] - The company is a member of the China Pharmaceutical Packaging Association and the National Packaging Standardization Technical Committee [1] - As of March 31, 2025, the number of shareholders is 18,803, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Financial Performance - In the first quarter of 2025, the company reported revenue of 162 million yuan, a year-on-year decrease of 34.24%, and a net profit of 10.91 million yuan, down 48.15% year-on-year [1] - The sales gross margin for the same period is 21.61% [1] Industry Summary - The average PE ratio for the medical device industry is 56.58 times, with a median of 39.97 times, placing Zhengchuan Co., Ltd. at the 96th position in the industry ranking [1][2] - The industry includes various companies with lower PE ratios, such as Jiuan Medical at 11.36 times and Yuyue Medical at 20.20 times [2]

Company Overview - Zhengchuan Co., Ltd. closed at 21.38 yuan, down 3.30%, with a rolling PE ratio of 74.98 times and a total market value of 3.233 billion yuan [1] - The company specializes in the research, production, and sales of pharmaceutical packaging materials, including borosilicate glass tubes and sodium-calcium glass tubes [1] - Zhengchuan is a member of the China Pharmaceutical Packaging Association and the National Packaging Standardization Technical Committee [1] Financial Performance - For Q1 2025, the company reported revenue of 162 million yuan, a year-on-year decrease of 34.24%, and a net profit of 10.9141 million yuan, down 48.15% year-on-year [1] - The sales gross margin for the latest quarter was 21.61% [1] Shareholder Information - As of March 31, 2025, the number of shareholders was 18,803, a decrease of 638 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Industry Comparison - The average PE ratio for the medical device industry is 55.76 times, with a median of 39.14 times, placing Zhengchuan at the 96th position in the industry ranking [1][2] - The industry average market value is 11.792 billion yuan, while the median is 5.679 billion yuan [2]

Company Overview - Zhengchuan Co., Ltd. closed at 22.31 yuan, down 1.85%, with a rolling PE ratio of 78.24 times and a total market value of 3.373 billion yuan [1] - The company operates in the pharmaceutical packaging materials sector, focusing on the research, production, and sales of medicinal glass tubes and other packaging materials [1] - Main products include borosilicate glass tubes, soda-lime glass tubes, aluminum caps, pre-filled syringes, and cassette bottles [1] Financial Performance - For Q1 2025, the company reported revenue of 162 million yuan, a year-on-year decrease of 34.24%, and a net profit of 10.9141 million yuan, down 48.15% year-on-year, with a gross margin of 21.61% [1] Shareholder Information - As of March 31, 2025, the number of shareholders was 18,803, a decrease of 638 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Industry Comparison - The average PE ratio for the medical device industry is 57.51 times, with a median of 41.25 times, placing Zhengchuan Co., Ltd. at the 96th position in the industry ranking [1][2] - Other companies in the industry have varying PE ratios, with the highest being 21.19 times for Antu Biology and the lowest at 11.26 times for Jiuan Medical [2]

转自：前瞻产业研究院 行业主要上市公司：力诺药包(301188.SZ)、山东药玻(600529.SH)、旗滨集团(601636.SH)、威高股份 (01066.HK)、正川股份(603976.SH)等 本文核心数据：产量;销量 2、"A"类与"I"类评审结果数量相当 1、关联评审流程 截至2025年，中国中硼硅玻璃包材"A"类与"I"类评审结果分布中，"A"类数量239个，占比47%，"I"类占 比53%。 最新修订的《中华人民共和国药品管理法》进一步明确规定：国务院药品监督管理部门在审批药品时， 对化学原料药一并审评审批，对相关辅料、直接接触药品的包装材料和容器一并审评，对药品的质量标 准、生产工艺、标签和说明书一并核准。原辅包登记平台上的"与制剂共同审评审批结果"标识改为两 种，即"A"和"I"，"A"代表已批准在上市制剂使用的原料/辅料/包材，"I"代表尚未通过与制剂共同审评 审批的原料/辅料/包材。 截至2025年中国中硼硅玻璃包材"A"类评审结果产品分布中，安瓿、输液瓶、注射剂瓶及其他分别为77 个、3个、116个和43个。 3、"A"评审结果国产数量多于进口 截至2025年中国中硼硅玻璃包材"A" ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Zhengchuan Co., which operates in the pharmaceutical packaging industry, specifically focusing on glass containers [1] - As of August 5, Zhengchuan Co. closed at 22.89 yuan, with a rolling PE ratio of 80.27 times, and a total market capitalization of 3.461 billion yuan [1] - The average PE ratio for the medical device industry is 54.24 times, with a median of 37.92 times, placing Zhengchuan Co. at the 101st position in the industry ranking [1][2] Group 2 - The latest quarterly report for Q1 2025 shows that Zhengchuan Co. achieved an operating revenue of 162 million yuan, a year-on-year decrease of 34.24%, and a net profit of 10.9141 million yuan, down 48.15% year-on-year, with a gross profit margin of 21.61% [1] - The company specializes in the research, production, and sales of pharmaceutical packaging materials, including borosilicate glass tubes and pre-filled syringes [1] - As of March 31, 2025, Zhengchuan Co. had 18,803 shareholders, a decrease of 638 from the previous count, with an average holding value of 352,800 yuan per shareholder [1]

Group 1 - The stock price of Zhengchuan Co., Ltd. closed at 22.56 yuan on August 4, 2025, down 0.74 yuan or 3.18% from the previous trading day [1] - The opening price was 22.79 yuan, with a highest point of 23.19 yuan and a lowest point of 21.75 yuan, with a trading volume of 77,300 hands and a transaction amount of 174 million yuan [1] - On the morning of August 4, Zhengchuan Co., Ltd. experienced a quick rebound, with a rise of over 2% within 5 minutes, reaching a price of 22.8 yuan [1] Group 2 - Zhengchuan Co., Ltd. specializes in the research, production, and sales of pharmaceutical glass packaging materials, primarily used in the fields of biopharmaceuticals and vaccines [1] - The company operates in sectors including medical devices and the Chongqing region [1] - On August 4, the net outflow of main funds was 11.9955 million yuan, with a cumulative net outflow of 9.5609 million yuan over the past five days [1]